DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Kynmobi is a drug marketed by Sunovion Pharms Inc and is included in one NDA. There are fourteen patents protecting this drug.
This drug has two hundred and thirty-six patent family members in twenty-four countries.
The generic ingredient in KYNMOBI is apomorphine hydrochloride. There are six drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the apomorphine hydrochloride profile page.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be December 16, 2031. This may change due to patent challenges or generic licensing.
There have been twenty-nine patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.
Indicators of Generic Entry
Summary for KYNMOBI
Generic Entry Opportunity Date for KYNMOBI
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
|Country||Patent Number||Estimated Expiration|
|European Patent Office||2079457||Start Trial|
|World Intellectual Property Organization (WIPO)||2008100375||Start Trial|
|>Country||>Patent Number||>Estimated Expiration|